Apex Affinity Selects Elsevier's Gold Standard Drug Database

         Apex Affinity Selects Elsevier's Gold Standard Drug Database

  PR Newswire

  TAMPA, Florida, May 20, 2013

TAMPA, Florida, May 20, 2013 /PRNewswire/ --

 Elsevier will provide Apex with essential drug information in a streamlined
                              database solution

Elsevier , a world-leading provider of scientific, medical and technical
information products and services, today announced an agreement with Apex
Affinity , provider of innovative prescription discount programs for uninsured
and underinsured families nationwide. Apex has selected Elsevier's Gold
Standard Drug Database for providing current and accurate drug content to
enhance its member products, including a new consumer drug reference portal.

Apex leverages the purchasing power of millions of consumers to negotiate deep
discounts on brand-name and generic prescriptions at nearly all major big box
stores, drug store chains and independent neighborhood pharmacies. Apex will
use Elsevier's Gold Standard Drug Database to enable members to compare drug
pricing, look-up accurate dosage information, and learn about alternative
therapies and what a medication is used for and what it does.

"With the Gold Standard Drug Database, we can provide our members with the
most up-to-date drug information in an easy to use format," said Scott Paul,
Apex's Chief Executive Officer. "It will help our members make informed
decisions about their medications and their health."

The Gold Standard Drug Database content is updated daily and has a
peer-reviewed editorial process in place to ensure the highest accuracy of
drug product information, drug pricing and patient education information. Apex
will benefit from the database's modern technical architecture and flexible
implementation, which distinguishes Gold Standard Drug Database from other
drug databases.

"With the implementation of our Gold Standard Drug Database, Apex will have
the confidence that their value-added consumer reference products contain
superior drug information that allows their members to swiftly and
effortlessly research their medications," said Trygve Anderson, R.Ph.

Vice President of Product Management, Elsevier's Gold Standard.

For more information about Elsevier's Gold Standard, please visit
http://www.goldstandard.com .

                                    # # #

About Apex Affinity

Apex Affinity provides innovative services that help organizations reach new
customers, increase satisfaction and loyalty, and create new revenue streams.
From traditional retail discount cards to the latest e-marketing technologies,
Apex enables affinity groups to engage their members, offer high-value
services, and grow. For more information, visit http://www.apexaffinity.com .

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Suite ,
which enhance the productivity of science and health professionals, and the
SciVal suite and MEDai's Pinpoint Review , which help research and health care
institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group plc , a world leading
provider of professional information solutions. The group employs more than
30,000 people, including more than 15,000 in North America. Reed Elsevier
Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed
Elsevier NV. Their shares are traded on the London, Amsterdam and New York
Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.

Media contact Christopher Capot Director, Corporate Relations, Elsevier
+1-212-633-3164 c.capot@elsevier.com
Press spacebar to pause and continue. Press esc to stop.